scholarly journals Meeting Unmet Needs in Patients With Sepsis: the Role of Drotrecogin Alfa (Activated)

2003 ◽  
Vol 12 (2) ◽  
pp. 94-97 ◽  
Author(s):  
Peter E. Morris
Keyword(s):  
Drotrecogin Alfa ◽  
Unmet Needs ◽  
Drotrecogin Alfa Activated

Role of Activated Protein C in the Pathophysiology of Severe Sepsis

2003 ◽  
Vol 12 (6) ◽  
pp. 518-524 ◽  
Author(s):  
Patricia Dettenmeier ◽  
Bridget Swindell ◽  
Mary Stroud ◽  
Nancy Arkins ◽  
April Howard
Keyword(s):  
Severe Sepsis ◽  
Protein C ◽  
Drotrecogin Alfa ◽  
Activated Protein C ◽  
Therapeutic Agents ◽  
Multiple Organ ◽  
Phase 3 ◽  
The Past ◽  
Drotrecogin Alfa Activated

Sepsis is a complex syndrome that can lead to multiple organ failure and death. Severe sepsis has been associated with mortality rates ranging from 28% to 50% and is the most common cause of death in the noncardiac intensive care unit. Despite advances in both antibiotic therapy and supportive care, the mortality rate due to severe sepsis has remained fundamentally unchanged in the past several decades. With increased understanding of the pathophysiology of sepsis, particularly the intricate interplay between activation of coagulation and inflammation, novel therapeutic agents that may improve clinical outcomes are being researched and developed. The epidemiology, pathophysiology, and treatment of severe sepsis are reviewed. Also discussed are the recently published results from a multicenter, randomized, placebo-controlled phase 3 clinical trial of drotrecogin alfa (activated), a recombinant form of human activated protein C, in patients with severe sepsis. The nursing implications of this new approved therapy are discussed.

Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis

2004 ◽  
Vol 53 (10) ◽  
pp. 528-533 ◽  
Author(s):  
M. Brueckmann ◽  
U. Hoffmann ◽  
E. Dvortsak ◽  
S. Lang ◽  
J. J. Kaden ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Drotrecogin Alfa ◽  
Mononuclear Cells ◽  
Nf Kappa B ◽  
Drotrecogin Alfa Activated

scholarly journals Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)

Critical Care ◽  
2008 ◽  
Vol 12 (Suppl 2) ◽  
pp. P205 ◽  
Author(s):  
J Dhainaut ◽  
M Antonelli ◽  
P Wright ◽  
M Belger ◽  
M Cobas-Meyer ◽  
...  
Keyword(s):  
Drotrecogin Alfa ◽  
Vasopressor Support ◽  
Drotrecogin Alfa Activated
Sign in / Sign up

Export Citation Format

Share Document